Curated News
By: NewsRamp Editorial Staff
November 24, 2025
Nutriband Chairman to Present at NobleCon21 Investor Conference
TLDR
- Nutriband's conference presentation offers investors early insights into their abuse-deterrent fentanyl patch technology for potential market advantage.
- Nutriband Chairman Serguei Melnik will present at NobleCon21 on December 3, with a webcast available the following day through nobleconference.com and Channelchek.com.
- Nutriband's AVERSA technology prevents abuse of transdermal drugs, making medication safer for patients and communities worldwide.
- Nutriband's innovative abuse-deterrent patch technology transforms how potent medications are delivered through the skin safely.
Impact - Why it Matters
This development matters because it represents a critical opportunity for investors to learn about innovative pharmaceutical safety technology that addresses the ongoing opioid crisis. Nutriband's AVERSA™ abuse-deterrent technology could significantly impact public health by preventing the misuse of potent pain medications like fentanyl, which has been responsible for thousands of overdose deaths annually. For investors, this presentation offers insight into a company developing solutions for a major healthcare challenge while potentially creating shareholder value. The timing is particularly relevant given increasing regulatory focus on opioid safety and the growing demand for abuse-deterrent formulations in the pharmaceutical industry.
Summary
Nutriband (NASDAQ: NTRB), a pharmaceutical development company, announced that Chairman and Co-Founder Serguei Melnik will present at NobleCon21, Noble Capital Markets' annual emerging growth equity conference. The presentation is scheduled for December 3rd at 9:30 a.m. Eastern Time at Florida Atlantic University's Executive Education Complex in Boca Raton, Florida. Investors and guests can attend at a discounted rate using the special code NTRBNOBLECON, while a high-definition webcast will be available the following day through nobleconference.com and Channelchek.com, where it will remain archived for 90 days, providing extended access to the investment community.
The company is primarily focused on developing transdermal pharmaceutical products, with its lead product being an abuse-deterrent fentanyl patch that incorporates their proprietary AVERSA™ technology. This innovative technology represents a significant advancement in pharmaceutical safety, as it can be integrated into any transdermal patch to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. The presentation at this prestigious financial conference represents a crucial opportunity for Nutriband to showcase its technology platform and business strategy to potential investors and industry stakeholders.
NetworkNewsWire, the specialized communications platform responsible for distributing this announcement, operates as part of the Dynamic Brand Portfolio within IBN, providing comprehensive financial news distribution services. The platform offers extensive reach through InvestorWire solutions, editorial syndication to over 5,000 outlets, enhanced press release services, and social media distribution to millions of followers. This robust distribution network ensures that Nutriband's message reaches a broad audience of investors, influencers, and industry professionals, maximizing the impact of their conference presentation and corporate communications strategy.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Nutriband Chairman to Present at NobleCon21 Investor Conference
